In pediatric acute lymphoblastic leukemia (ALL), overexpression of murine double minute 2 (MDM2) protein by leukemic cells is typically associated with a wild-type (wt)-p53 phenotype and chemoresistance. A recently developed small-molecule antagonist of MDM2, nutlin-3, inhibits the MDM2-p53 interaction, resulting in induction of p53 activity and apoptosis. In this study, we evaluated the cytotoxic effect of nutlin-3 on ALL cells with different p53 status and MDM2 expression, using 18 cell lines and 30 primary leukemia samples. We found that both ALL cell lines and primary ALL samples with wt-p53 are sensitive to nutlin-3. No cytotoxic effect of nutlin-3 was detected in ALL cells with either p53-mutant or -null phenotype. In wt-p53 ALL cells, there was a significant positive correlation between MDM2 expression levels and sensitivity to nutlin-3. Nutlin-3-induced cell death was mediated by p53-induced activation of proapoptotic proteins and by p53-induced repression of the anti-apoptotic protein survivin. As p53 function is inhibited by MDM2 in chemoresistant, MDM2-overexpressing ALL cells, potent killing of these cells by nutlin-3 suggests that this agent may be a novel therapeutic for refractory ALL.
Introduction
Inactivation of the p53 gene has been implicated in chemoresistance and poor prognosis in a wide variety of human malignancies. Inactivation occurs by gene mutation in approximately 50% of solid tumor patients; 1,2 however, gene mutations conferring inactivation of p53 appear to be relatively infrequent in leukemia. In childhood acute lymphoblastic leukemia (ALL), p53 mutations have been detected in some patients (5-10%) undergoing relapse and in cell lines established from these patients. 3, 4 At initial diagnosis, the incidence of p53 mutation appears to be low (o5%). 5 Although loss of p53 expression as a result of intronic mutation has been detected in some ALL cell lines, 6, 7 it does not appear to be a common mechanism for inactivation of p53 in ALL patients. Thus, most cases of ALL express wild-type (wt)-p53. However, inactivation of p53 due to overexpression of the human homolog of the murine double minute 2 (hMDM2) protein has been observed in 20-30% of human ALL patients. [8] [9] [10] [11] Furthermore, hMDM2 overexpression in these patients is associated with chemoresistance and poor treatment outcome. [11] [12] [13] [14] [15] First identified as a small acrocentric extrachromosomal element that becomes oncogenic after amplification and overexpression in NIH-3T3 cells, the human MDM2 gene has now been mapped to chromosome 12q13-14, a region amplified in a variety of human cancers. 16 In addition, high levels of MDM2 expression can occur in malignancies without any MDM2 gene amplification, such as in leukemia. 8 Structurally, the MDM2 protein contains several highly conserved domains at the amino-acid sequence level. These include an N-terminal domain, a central acidic domain adjacent to a zinc-finger domain and a C-terminal RING finger domain. In addition, MDM2 contains a nuclear localization sequence and a nuclear export sequence that promote nuclear import and export of the MDM2, respectively. MDM2 gained considerable attention following its identification as the protein that negatively regulates p53. The N terminus of the MDM2 protein binds to p53, restraining p53-mediated transcription, 17 and the C terminus of MDM2 acts as an E3 ubiquitin ligase, tagging p53 for proteasome-mediated degradation. 18 To bind p53 and inhibit its transcriptional activity, MDM2 must localize in the nucleus. Previous studies have shown that the nuclear localization of MDM2 is regulated by the PI3K/Akt pathway. 19, 20 Cell growth and survival factor-induced activation of PI3K and its downstream target Akt allows for phosphorylation of cytoplasmic MDM2 on both serine 166 and serine 186, which lie within close proximity to nuclear localization sequence and nuclear export sequence. Phosphorylation of these sites is required for the translocation of MDM2 from the cytoplasm to the nucleus, where it can exert a p53-inhibitory function.
The MDM2 antagonist nutlin-3 was recently identified as an agent that can block interactions between MDM2 and p53. 21 This nongenotoxic compound binds to the p53-binding pocket in the MDM2 protein, thus inhibiting the binding of p53 and activating the p53 pathway in cancer cells with wt-p53. Treatment with this small-molecule drug selectively induces cell cycle arrest, growth inhibition and apoptosis in a variety of human cancers with wt-p53, including prostate and lung carcinoma, 22, 23 neuroblastoma, 24 Hodgkin's lymphoma, 25 multiple myeloma, 26 acute myelogenous leukemia 27 and chronic lymphocytic leukemia. 28, 29 In this study, we tested the effect of nutlin-3 on ALL cells. Our results demonstrated that nutlin-3 exhibits cytotoxic activity against wt-p53 ALL cells, including both ALL cell lines and primary ALL cells. In particular, nutlin-3 potently killed wt-p53 ALL cells overexpressing MDM2. These results should be important clinically, as ALL patients with leukemic cells overexpressing MDM2 are usually resistant to conventional chemotherapy and have a poor prognosis. Therefore, nutlin-3 may be a novel therapeutic agent for improved treatment of refractory ALL patients.
Materials and methods

Cell lines and primary leukemia cells
Eighteen established cell lines originating from children with ALL were studied. Nine of these cell lines (EU-1 through EU-9) were established at Emory University (Atlanta, GA, USA), and  seven (SUP-B13, SUP-BI5, UOC-BI, UOC-B3, UOC-B4,  UOCB11 and KT) were obtained from Stephen D Smith (University of Kansas City, KS, USA). The Reh ALL cell line was obtained from C Rosenfeld (INSERM, Villejuif, France) and CCRF-CEM was obtained from the American Type Culture Collection (Rockville, MD, USA). The phenotypes of these cell lines, including p53 status and MDM2 expression level, were characterized in prior publications 9 and are summarized in Table 1 . The cell lines were grown in standard culture medium (RPMI 1640 containing 10% fetal bovine serum, 2 mmol l À1 L-glutamine, 50 U penicillin and 50 mg ml À1 streptomycin) at 37 1C in 5% CO 2 .
Patients included in this study were treated for ALL (either diagnosis or first relapse) at Emory and other institutions. Following informed consent, pretreatment bone marrow specimens were obtained from 30 patients with ALL including 11 cases in initial diagnosis and 19 at relapse. Of these 30 patients, 25 had B-cell precursor-ALL and 5 had T-ALL, as diagnosed by standard immunologic, morphologic and cytochemical criteria. The mononuclear cells were separated by centrifugation on FicollHypaque (1.077 g ml À1 ), washed twice in phosphate-buffered saline (PBS) and resuspended at a density of 10 6 cells per ml in RPMI 1640 containing 10% fetal bovine serum. The cells were incubated on plastic Petri dishes for 1 h at 37 1C to remove the monocytes, and then the nonadherent cells were recovered by gently washing the dishes. All specimens collected for these studies contained more than 90% blasts following purification.
Nutlin-3 treatment
The small-molecule antagonist of MDM2, nutlin-3, purchased from Cayman Chemical (Ann Arbor, MI, USA), was dissolved in ethanol to create a 10 mM stock solution and stored in small aliquots at À20 1C. Cells were exposed to 0-10 mM of nutlin-3 for the time period indicated, with the final ethanol concentration kept constant in each experiment (note: this is combination of equimolar amounts of nutlin-3a (active) and 3b (inactive) isomers; thus, concentrations of active isomer are equal to 50% of total concentration).
Quantitative RT-PCR and DNA sequencing of p53
The total RNA was extracted from cells with the RNeasy Mini Kit (Qiagen, Hilden, Germany). First-strand cDNA synthesis was performed with a mixture of random nonamers and oligo-dT as primers (Qiagen). Amplification of MDM2, p53, p21, Bax, PUMA and survivin genes in ALL cells was performed with a 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), using the QuantiFast SYBR Green RT-PCR kit (Qiagen) according to the manufacturer's instructions. All specific primers for amplification of these genes as well as the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were purchased from Qiagen (sequences of the primers not provided). After normalization for GAPDH, expression levels of MDM2, p53, p21, Bax, PUMA and survivin in nutlin-3-treated and untreated cells were determined.
For the p53 mutation analysis, total RNA extraction and cDNA synthesis were performed as detailed above. The entire coding region of p53 was PCR amplified in two overlapping fragments, using the following two primer pairs: forward, 
Western blot analysis
Cells were lysed for 30 min at 4 1C in a buffer composed of 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 1% (v/v) Concentration of nutlin-3.
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Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 20 mg ml À1 aprotinin and 25 mg ml À1 leupeptin. Equal amounts of protein extracts (10 mg) were resolved by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose filter. After blocking for 1 h at room temperature with buffer containing 20 mM Tris-HCl (pH 7.5), 500 mM NaCl and 5% nonfat milk, the filter was incubated with specific antibodies for 3 h at room temperature. After washing, the filter was incubated with a horseradish peroxidase-labeled secondary antibody for 1 h. Finally, the blots were developed using a chemiluminescent detection system (ECL, Amersham Life Science, Buckinghamshire, England).
siRNA transfection
The survivin siRNA was purchased from Invitrogen, Carlsbad, CA, USA. A mismatched siRNA was used as a control. Transfection of siRNA into cells was performed using siPORTNeoFX reagent (Ambion, Austin, TX, USA). Briefly, cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum to a density of 1 Â 10 6 per ml. The siRNA solution and siPORTNeoFX reagent were diluted in OPTI-MEMI media and mixed following the manufacturer's protocols, and then the prepared cells were added to the plates containing these siRNA/ siPORTNeoFX complexes. Cells were incubated at 37 1C until ready to assay. All treatments were performed in triplicate.
WST assay
The cytotoxic effect of nutlin-3 and doxorubicin on ALL cells was determined with the water-soluble tetrazolium salt (WST) assay. Briefly, cells were cultured in 96-well microtiter plates with different concentrations of nutlin-3, for a 44 h period. Then, WST (25 mg per well) was added and the cells were incubated for an additional 4 h. Following incubation, the optical density of the wells was read with a microplate reader set at a test wavelength of 450 nm and a reference wavelength of 620 nm. Appropriate controls lacking cells were included to determine background absorbance.
Flow cytometry
Flow cytometry was performed to analyze the cell cycle position after annexin-V staining to reveal apoptotic cells. Following nutlin-3 treatment, 5 Â 10 5 cells were collected, rinsed twice with PBS and fixed in 70% ethanol for 1 h at 4 1C. Cells were then washed twice in PBS and resuspended in 30 ml of phosphate citrate buffer (0.1 M Na citrate/0.2 M Na 2 HPO 4 ) for 30 min at room temperature. The samples were rewashed with PBS and suspended in 0.5 ml PBS containing 20 mg ml À1 of propidium iodide and 20 mg ml À1 of RNase A. After incubating at 4 1C for at least 0.5 h, the samples were analyzed using a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA) and WinList software (Verity Software House Inc.). For quantitation of apoptotic cells by annexin-V staining, cells with or without nutlin-3 treatment were washed once with PBS and stained with FITC-annexin-V and propidium iodide, according to the manufacturer's instructions. Stained cells were analyzed as outlined above.
Statistical analysis
For testing the relationship between MDM2 expression and nutlin-3 sensitivity, the w 2 test was utilized. The two-tailed Student's t-test was used for comparison of the means between groups, using a significance level of Po0.05. Unless otherwise indicated, average values were expressed as mean±s.d.
Results
Nutlin-3 is cytotoxic for ALL cell lines with wt-p53 but not p53-mutant or -null phenotype
The 18 ALL cell lines used in this study have been previously characterized for their p53 status and MDM2 expression. 9 This characterization is summarized in Table 1 . Of the 18 ALL cell lines, 14 were B-cell precursor-ALL and 4 were T-ALL. The p53 protein is expressed in 13 cell lines. Four of these cell lines express mutant p53, whereas nine express wt-p53. The remaining five cell lines fail to express both wt-p53 mRNA and protein (p53-null phenotype). As previously detected by northern blot assay, all nine functional wt-p53 ALL cell lines overexpress MDM2 mRNA. 9 Quantitative reverse transcription (RT)-PCR assays performed in our study further confirmed that all wt-p53 cell lines express high levels of MDM2, as compared to the ALL cell lines with p53-mutant or -null phenotype, although the expression levels varied from line to line (Table 1 and Figure 1a ).
We first examined the effect of nutlin-3 on the viability and cell survival of cultured ALL cell lines using the WST cytotoxic assay. Nutlin-3 exhibited dose-dependent cytotoxic activity in all nine wt-p53-expressing ALL cell lines (Table 1 and Figure 1b) . In contrast, all cell lines having either p53-mutant or -null phenotype failed to respond to nutlin-3, confirming that nutlin-3 is cytotoxic only to cells with wt-p53. 21 To clarify whether cell death induced by nutlin-3 in wt-p53 ALL cells was associated with induction of apoptosis, the annexin-V apoptosis assay was used. Consistent with the results of the WST cytotoxic assay, nutlin-3 treatment induced dose-and time-dependent apoptosis in the wt-p53-expressing cell lines, but not in lines with a p53-mutant or -null phenotype (Table 1 and Figure 1c ). Nutlin-3-induced apoptosis in wt-p53 but not mutant cells was further confirmed by a western blot assay evaluating activation of caspase-3 and cleavage of the death substrate poly(ADPribose) polymerase (PARP). As shown in Figure 1d , significant cleavage of caspase-3 and PARP was detected 8 h after nutlin-3 treatment of wt-p53 UOC-B3 cells, whereas cleavage of these two proteins was not observed in the p53-mutant EU-6 cells, even 48 h after treatment.
Nutlin-3 strongly induces apoptosis in primary ALL cells with wt-p53 and MDM2 overexpression
Owing to a growth advantage and positive selection, established ALL cell lines have a high frequency of p53-mutant or -null phenotype relative to leukemic cells at diagnosis. Furthermore, wt-p53 ALL cell lines typically exhibit a high level of MDM2 expression, whereas the primary wt-p53 ALL cells taken from most patients express no or low levels of MDM2. To evaluate whether the p53 pathway remains functional in primary ALL cells and could thus be exploited for therapy, we analyzed the cytotoxic effect of nutlin-3 on freshly isolated primary ALL cells collected from 30 patients. The patient sample characteristics are shown in Table 2 . The MDM2 mRNA levels are shown relative to an internal control, GAPDH, as determined by quantitative RT-PCR. As an experimental control, primary ALL results were compared with the level of MDM2 mRNA in normal marrow mononuclear cells (NMMCs). As listed in Table 2 , ALL cells from 6 of the 30 patients (20%) overexpressed MDM2 (greater than 10-fold over NMMC values). The leukemic cells from 6 other patients expressed MDM2 at low levels (2-to 10-fold above NMMCs), while cells from the remaining 18 patients expressed MDM2 at less than twofold the level in NMMCs (indicated by a dash in Table 2 ). Western blot analysis confirmed that ALL cells expressing high levels of MDM2 mRNA also overexpressed the MDM2 protein (Figure 2a) . One patient's ALL cells (UPN 2) had a p53 mutation in exon 7, in codon 248.
All samples from the 30 ALL patients were examined for their response to nutlin-3. Nutlin-3 exhibited dose-dependent cytotoxicity for primary wt-p53 ALL cells (Figure 2b ). There was a significant case-to-case difference in IC 50 values for nutlin-3 ( Figure 3a ). Sensitivity to nutlin-3 appeared to be unrelated to patient gender, age, WBC count and immunophenotypes (B and T cells). However, response to nutlin-3 did appear to be tightly associated with the p53 status of the ALL blasts. Similar to results for the ALL cell lines, nutlin-3 did not show a cytotoxic effect on p53-mutant primary cells from UPN 2 (Figure 2b) . Similarly, nutlin-3 was not significantly cytotoxic to normal NMMCs (Figure 2b) .
Interestingly, the cytotoxic activity of nutlin-3 was correlated with MDM2 expression levels in the wt-p53 ALL cells. We found that nutlin-3 was extremely cytotoxic for the ALL cell line UOC-B3 with the highest level of MDM2, but was less cytotoxic for Reh cells with relatively low levels of MDM2 (Figure 1b) .
Although we have not analyzed the remaining 7 wt-p53 cell lines for the correlation between MDM2 levels and nutlin-3-induced cytotoxicity, we have evaluated the correlation between the IC 50 value of nutlin-3 and the MDM2 level in 29 wt-p53 primary ALL samples. On the basis of MDM2 expression, the 29 samples were divided into three groups: MDM2À (n ¼ 18), MDM2 o10 Â (n ¼ 5) and MDM2 410 Â (n ¼ 6). As shown in Figure 3a , the 11 ALL patient samples having MDM2 expression showed increased in vitro sensitivity to nutlin-3. Of these 11 cases, the 6 with MDM2 overexpression (410 Â ) were highly sensitive to nutlin-3 (mean IC 50 ¼ 1 mM), as compared to the 5 cases where MDM2o10 Â (mean IC 50 ¼ 1.68 mM) (Po0.05) and the 18 MDM2-negative cases (mean IC 50 ¼ 5.52 mM) (Po0.01). In addition, by analyzing the 11 MDM2-expressing primary ALL samples for the association between MDM2 expression levels and nutlin-3-induced cytotoxicity, we found a significant positive correlation between the relative MDM2 level and percent cytotoxicity (r ¼ 0.823, Po0.01; Figure 4) . Interestingly, Figure 3b shows that the MDM2-overexpressing/nutlin-3-sensitive ALL samples were all significantly resistant to doxorubicin (mean IC 50 ¼ 1.46 mM). By comparison, the MDM2-negative samples that were relatively resistant to nutlin-3 were not resistant to doxorubicin (mean IC 50 ¼ 0.41) (Po0.05). ); wt, wild type. a MDM2: relative amount of mRNA compared with that in normal marrow mononuclear cells (NMMCs, defined as 1 unit); F, less than onefold compared with NMMCs.
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Nutlin-3-induced cell death is associated with the activation of p53 function in ALL cells
It is clear that nutlin-3 induces cell death through cell cycle arrest and apoptosis regulated by activation of p53 and its transcriptional targets; these include several proapoptotic genes such as p21, Bax and PUMA. We tested the effect of nutlin-3 on the induction of these genes in ALL cells. In particular, we wondered whether any differences in the apoptotic response induced by nutlin-3 in ALL cells are correlated with the induction levels of these genes. We compared a pair of wt-p53 primary ALL samples UPN 3 and UPN 18 for induction of p21, Bax and PUMA as well as p53 following nutlin-3 treatment; these samples were chosen because UPN 3 and UPN 18 have the same immunophenotype, karyotype and high WBC count but exhibit significant differences in MDM2 expression and sensitivity to nutlin-3. We found that p53, p21, Bax and PUMA were remarkably induced by nutlin-3 in MDM2-overexpressing/nutlin-3-sensitive UPN The p53-survivin signaling pathway contributes to nutlin-3-induced apoptosis in ALL It is known that cellular stress and DNA damage induce activation of p53, resulting in downregulation of the inhibitorof-apoptosis protein (IAP) survivin gene transcription, which plays a critical role in regulating apoptosis in wt-p53 cancer cells. We evaluated whether activation of p53 by the nongenotoxic nutlin-3 also represses survivin expression in wt-p53 ALL cells. Similarly, we compared UPN 3 and UPN 18 for reduction of survivin following nutlin-3 treatment. We found that survivin was remarkably inhibited by nutlin-3 in MDM2-overexpressing/nutlin-3-sensitive UPN 3 cells. As shown in Figures 5c and d , approximately five-to sixfold amounts of survivin mRNA and protein were suppressed by nutlin-3. In contrast, a similar treatment of nutlin-3 reduced much lower (one-to twofold) expression of survivin in MDM2-negative/ nutlin-3-resistant UPN 18. In addition, we examined survivin expression in nutlin-3-treated wt-p53 ALL cell line as compared to the mutant-p53 ALL cell line. In the wt-p53 UOC-B3 ALL cell line, survivin expression was remarkably downregulated after 2-4 h and was barely detectable following 8 h of nutlin-3 treatment (Figure 6a ). The expression of two other IAP members, cIAP1 and cIAP2, Positive correlation between MDM2 levels and nutlin-3-induced cytotoxicity in primary acute lymphoblastic leukemia cells. MDM2 mRNA expression levels relative to GAPDH were determined by quantitative reverse transcription-PCR in each sample and then compared with the normal marrow mononuclear cells from 11 MDM2 protein-positive leukemia cases, as detected by western blot. The cytotoxic effect of nutlin-3 was detected by WST analysis.
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L Gu et al was tested as controls and remained unchanged in the UOC-B3 cells after nutlin-3 treatment. Although the anti-apoptotic protein Bcl-2 is a transcriptional target of p53, nutlin-3 was not found to alter Bcl-2 expression in the UOC-B3 cells. In the mutant-p53 EU-6 cells, nutlin-3 treatment did not affect the expression of survivin, cIAP1, cIAP2 or Bcl-2.
To further confirm the role of survivin downregulation in apoptosis in response to nultlin-3, we tested whether inhibition of endogenous survivin by siRNA can also induce apoptosis in ALL cells. We purchased a specific survivin siRNA, from Invitrogen, that has been shown to effectively inhibit survivin expression. Survivin siRNA transfection suppressed expression of survivin in both UOC-B3 (Figure 6b ) and EU-6 (data not shown) in a dose-dependent manner. Inhibition of survivin by siRNA resulted in apoptosis of both UOC-B3 (Figure 6c ) and EU-6 (Figure 6d ) cells. A control siRNA did not induce apoptosis, suggesting that apoptosis in UOC-B3 and EU-6 is induced specifically by downregulation of survivin.
Discussion
As the majority of patients with hematopoietic malignancies have a wt-p53 phenotype, a recently developed inhibitor of the p53-MDM2 interaction, nutlin-3, has been extensively studied in a variety of these malignancies (including Hodgkin's lymphoma, multiple myeloma, acute myelogenous leukemia and chronic lymphocytic leukemia) for its role in inducing p53-dependent apoptosis and as a possible therapeutic agent. [25] [26] [27] [28] [29] In this study, we tested the response of pediatric ALL cells to nutlin-3-induced cytotoxicity and apoptosis. We demonstrated that ALL cell lines and primary ALL cells with wt-p53 responded to nutlin-3. Furthermore, the cytotoxic response occurred in a dose-and time-dependent manner. The cytotoxic activity of nutlin-3 on ALL cells appeared to be unrelated to the patient's age, WBC count, T and B immunophenotypes and karyotype, all of which have been proposed to be prognostic factors for pediatric ALL. 30 The response of ALL cells to nutlin-3 was tightly associated with the p53 status. Cell lines and primary cells harboring a p53 mutation or having a p53-null phenotype did not respond to nutlin-3. More specifically, we found that the degree of induction of p53 function and apoptosis in ALL cells following treatment was positively correlated with the MDM2 levels in the cells.
In ALL, p53 gene mutations are rare at diagnosis. However, there is a higher incidence of p53 mutation or loss of p53 expression observed in ALL cell lines established at relapse. We studied 18 ALL cell lines (9 cell lines with wt-p53, 4 lines with p53 mutations and 5 lines with a p53-null phenotype) for their response to nutlin-3. Consistent with the results obtained with 
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L Gu et al certain other solid tumor or leukemic cell lines, 24, 27 nutlin-3 failed to induce cytotoxicity and apoptosis in the p53-mutant and -null ALL cell lines. Previous characterization showed that in ALL cell lines with a wt-p53, its presence is always associated with a high level of MDM2 expression, 9 suggesting that the p53 function is severely inhibited in this type of leukemic cell line. In all wt-p53 ALL cell lines, treatment with nutlin-3 induced significant cytotoxicity and apoptosis without being combined with any other chemotherapeutic drugs. At a concentration of 5 mM for 24 h, nutlin-3 induced over 50% apoptosis in six of the nine wt-p53 lines, and it induced 80% apoptosis in UOC-B3 cells, which express the highest level of MDM2. This suggests that nutlin-3 elicits a potent induction of p53 function in wt-p53/ MDM2-overexpressing ALL cell lines.
Unlike ALL cell lines, primary ALL cells from the majority of pediatric patients with a normal p53 do not express high levels of MDM2. However, in our previous study of 42 relapsed pediatric ALL patients, we found that leukemic cells from 2 of these patients had a p53 mutation and 12 of the remaining wt-p53 patients overexpressed MDM2 (10-fold higher than NMMCs).
11 Thus, we found an incidence of 28% MDM2 overexpression among these patients. Thirty cases, including the two mutant-p53 cell lines, expressed no or low levels of MDM2. Of these, 17 cases lacked MDM2 protein expression.
In this study, we evaluated whether the p53 function can be induced in the MDM2-negative cases as well. We tested for the cytotoxic effects of nutlin-3 on primary ALL samples from 30 patients. Similar to our findings with the ALL cell lines, nutlin-3 was not cytotoxic for the mutant-p53 case, while all 29 cases with wt-p53 responded to nutlin-3. These results suggest that the p53 function is also induced in ALL cells without MDM2 expression. However, the induction of p53 function and apoptosis was much lower in the MDM2-negative cases, as compared to the MDM2-expressing samples. In fact, there was a positive correlation between the levels of MDM2 expression and the degree of cytotoxicity occurring due to inhibition of MDM2 in ALL cells.
Nutlin-3 is a specific activator of the p53 pathway. Our results, which were consistent with those obtained for other types of cancer, [22] [23] [24] [25] [26] [27] [28] [29] showed that nutlin-3 induced upregulation of p53 in ALL cells. The p53-regulated proapoptotic genes p21, Bax and PUMA were activated following nutlin-3 treatment, although the degree of activation varied from case to case. We noted that the degree of induction of p53 and its transcriptional Nutlin-3 induces apoptosis in ALL cells L Gu et al targets following nutlin-3 treatment was correlated with the level of MDM2 protein present. We compared two cases, UNP 3 with MDM2 overexpression and UPN 18 with no MDM2 expression, for the induction of p53, p21, Bax and PUMA after nutlin-3 treatment. Results from both RT-PCR and western blot analysis showed that there was a greater induction of p53, p21, Bax and PUMA in MDM2-overexpressing ALL cells than in MDM2-negative cells. This probably explains why nutlin-3 exhibited much more potent cytotoxic activity toward MDM2-overexpressing ALL cells, as compared to MDM2-negative ALL cells.
Aside from induction of p53-dependent proapoptotic targets, p53 has also been shown to promote apoptosis by repressing transcription of the anti-apoptotic gene survivin. [31] [32] [33] The survivin gene promoter contains a p53 response element, and increased expression of p53 either by gene transfection or by cellular stress and DNA damage represses survivin promoter activity, resulting in decreased survivin protein expression and increased apoptosis. 32 In this study, we investigated whether nutlin-3 inhibits survivin expression by activating p53. Our results demonstrated that nutlin-3 treatment downregulated survivin expression at both mRNA and protein levels in wt-p53 primary ALL cells, with a greater downregulation in MDM2-overexpressing/nutlin-3-sensitive ALL cells than in MDM2-negative/nutlin-3 less sensitive cells. Further experiments in ALL cell lines showed that survivin downregulation by nutlin-3 occurred only in wt-p53 but not in mutant-p53 cells, which was consistent with apoptosis induction by nutlin-3 in wt-p53 but not mutant-p53 cells. Furthermore, inhibition of survivin by siRNA resulted in apoptosis in both wt-p53 and mutant-p53 ALL cells, implying that nutlin-3-induced downregulation of survivin mediated by wt-p53 also contributed to cell death. Taken together, our results suggested that the activity of nutlin-3 on ALL cells is due to increased p53-mediated activity, both through induction of proapoptotic factors and repression of the antiapoptotic gene survivin.
Acute lymphoblastic leukemia is the most common malignant disease in children. Despite the high rates of remission induction and survival that have been achieved with the current treatment regimens, approximately 20-25% of children with ALL do not respond well to therapy. These ALL patients either fail initial induction therapy or relapse after a short remission. 34 Resistance to chemotherapy-induced apoptosis is believed to be an important reason for the refractory disease. Most chemotherapeutic agents used in ALL treatment, including glucocorticoids, vincristine and doxorubicin, induce cell growth inhibition and apoptosis that are linked to p53 function. [35] [36] [37] Particularly, doxorubicin-induced cell death has been well characterized as occurring through DNA damage and induction of p53-dependent apoptosis. 38 It has been reported that overexpression of MDM2 by leukemic cells from childhood ALL patients was associated with early treatment failure. 13 In this study, we demonstrated that primary ALL cells with MDM2 overexpression are resistant to doxorubicin, with a mean IC 50 value for doxorubicin equal to 1.46 mM in 6 MDM2-overexpressing cases, as compared to 0.41 mM in 18 MDM2-negative cases. Moreover, MDM2-overexpressing/doxorubicin-resistant ALL cases were significantly more sensitive to nutlin-3 (mean IC 50 ¼ 1 mM) than MDM2-negative/doxorubicin-sensitive cases (mean IC 50 ¼ 5.52 mM).
Studies in ALL have indicated that in vitro drug sensitivity and apoptosis induction are predictive for treatment outcome and prognosis. [39] [40] [41] Studies in breast tumors also suggest that patient survival can be predicted by testing for in vitro sensitivity to doxorubicin. 42 We have previously demonstrated that the in vitro resistance of ALL cells to doxorubicin not only correlates with MDM2 expression, but is also associated with the duration of the first remission in ALL patients prior to relapse. 11 As nutlin-3 is specifically cytotoxic to ALL cells that overexpress MDM2 and are resistant to doxorubicin, our work suggests that nutlin-3 should be particularly useful for the treatment of high-risk, refractory ALL patients.
